Shall we dance: evolving partnerships of targeted therapies for AML
Two publications detailing the clinical outcomes of patients with acute myeloid leukemia and mutations in IDH1, IDH2, or FLT3 who received initial therapy with venetoclax and azacitidine provide new insights into risk stratification and set the stage for future trials integrating molecularly targete...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Association for Cancer Research
2022
|
| _version_ | 1797109985758412800 |
|---|---|
| author | Perl, AE Vyas, P |
| author_facet | Perl, AE Vyas, P |
| author_sort | Perl, AE |
| collection | OXFORD |
| description | Two publications detailing the clinical outcomes of patients with acute myeloid leukemia and mutations in IDH1, IDH2, or FLT3 who received initial therapy with venetoclax and azacitidine provide new insights into risk stratification and set the stage for future trials integrating molecularly targeted therapy with this new standard regimen. See related articles by Konopleva et al., p. 2744 and Pollyea et al., p. 2753. |
| first_indexed | 2024-03-07T07:48:53Z |
| format | Journal article |
| id | oxford-uuid:b6799f12-23b9-48ef-a13f-e4cd65e8d7f2 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:48:53Z |
| publishDate | 2022 |
| publisher | American Association for Cancer Research |
| record_format | dspace |
| spelling | oxford-uuid:b6799f12-23b9-48ef-a13f-e4cd65e8d7f22023-07-03T09:21:50ZShall we dance: evolving partnerships of targeted therapies for AMLJournal articlehttp://purl.org/coar/resource_type/c_6501uuid:b6799f12-23b9-48ef-a13f-e4cd65e8d7f2EnglishSymplectic ElementsAmerican Association for Cancer Research2022Perl, AEVyas, PTwo publications detailing the clinical outcomes of patients with acute myeloid leukemia and mutations in IDH1, IDH2, or FLT3 who received initial therapy with venetoclax and azacitidine provide new insights into risk stratification and set the stage for future trials integrating molecularly targeted therapy with this new standard regimen. See related articles by Konopleva et al., p. 2744 and Pollyea et al., p. 2753. |
| spellingShingle | Perl, AE Vyas, P Shall we dance: evolving partnerships of targeted therapies for AML |
| title | Shall we dance: evolving partnerships of targeted therapies for AML |
| title_full | Shall we dance: evolving partnerships of targeted therapies for AML |
| title_fullStr | Shall we dance: evolving partnerships of targeted therapies for AML |
| title_full_unstemmed | Shall we dance: evolving partnerships of targeted therapies for AML |
| title_short | Shall we dance: evolving partnerships of targeted therapies for AML |
| title_sort | shall we dance evolving partnerships of targeted therapies for aml |
| work_keys_str_mv | AT perlae shallwedanceevolvingpartnershipsoftargetedtherapiesforaml AT vyasp shallwedanceevolvingpartnershipsoftargetedtherapiesforaml |